Risk stratification for meningiomas with discordant molecular classification
Acta Neuropathologica · 24.06.2026 · 151 (1)
DOI: 10.1007/s00401-026-03038-x ↗Kurz gefasst
Leserbrief in der Zeitschrift Acta Neuropathologica, online erschienen am 24.06.2026. Verfasst von Brooke C Braman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA. Die Arbeit nennt 14 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA.
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA.
- Department of Pathology, University of California, San Francisco, San Francisco, CA, USA.
- Department of Radiation Oncology, University of California San Francisco, San Francisco, CA, USA. david.raleigh@ucsf.edu.
- Department of Neurological Surgery, University of California San Francisco, San Francisco, CA, USA. david.raleigh@ucsf.edu.
- Department of Pathology, University of California, San Francisco, San Francisco, CA, USA. david.raleigh@ucsf.edu.
Zitieren
APA
Braman, B. C., Aggarwal, A., Nguyen, M. P., Mirchia, K., Chen, W. C., & Raleigh, D. R. (2026). Risk stratification for meningiomas with discordant molecular classification. Acta Neuropathologica, 151(1). https://doi.org/10.1007/s00401-026-03038-x
Vancouver
Braman BC, Aggarwal A, Nguyen MP, Mirchia K, Chen WC, Raleigh DR. Risk stratification for meningiomas with discordant molecular classification. Acta Neuropathologica. 2026;151(1). doi:10.1007/s00401-026-03038-x
BibTeX
@article{Braman2026,
author = {Braman, Brooke C and Aggarwal, Ayush and Nguyen, Minh P and Mirchia, Kanish and Chen, William C and Raleigh, David R},
title = {Risk stratification for meningiomas with discordant molecular classification},
journal = {Acta Neuropathologica},
year = {2026},
volume = {151},
number = {1},
doi = {10.1007/s00401-026-03038-x}
}
EUVIMED